Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Therapeutic
- cardiac
- Disease
- Pharmaceuticals
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26860
License Grant
The Company acquired exclusive rights from Licensor, an individual, to a United States patent issued in September 1989, covering a method of reducing mortality associated with chronic CHF in patients with impaired cardiac function by administering a combination of specified amounts of hydralazine and isosorbide dinitrate.
License Property
BIDIL® – an oral dosage formulation containing the combination of hydralazinehydrochloride and isosorbide dinitrate (two generically available vasodilators) – subject to FDA approval, as to which no assurance can be given, proposed to be used to improve symptoms and survival in patients with congestive heart failure (CHF) who are inappropriate for treatment with angiotensin – converting enzyme (ACE) inhibitors.
Field of Use
In March 1993, the Company submitted to the FDA an IND to commence human bioequivalency studies in the U.S. Phase III clinical testing has been completed.
IPSCIO Record ID: 240585
License Grant
The Parties have agreed to collaborate together in order to develop, improve, and commercialize therapeutics for the treatment of cardiovascular disease based upon Licensors proprietary technology.
Licensor, an individual, grants an exclusive, worldwide right and license during the term of this Agreement under all of Licensors rights in the Patent Rights and Technical Information to make, have made, use, have used, sell, have sold, and import, Collaboration Products.
License Property
Licensor has developed certain proprietary technology related to the combination of hydralazine and isosorbide dinitrate for the treatment of cardiovascular disease.
The patent is for Method of Reducing Mortality Associated with Congestive Heart Failure Using 1-Hydralazine and Isosorbide Dinitrate.
Field of Use
The field shall mean the combination of hydralazine and isosorbide dinitrate, with or without one or more additional active ingredients for the treatment of cardiovascular diseases.
IPSCIO Record ID: 995
License Grant
Under the terms of its strategic License Agreement with the Licensor holding ownership rights to certain clinical trial data of Gencaro, the Licensee will incur milestone and royalty obligations upon the occurrence of certain events.
License Property
GencaroTM (bucindolol hydrochloride) is a pharmacologically unique beta-blocker and mild vasodilator for chronic heart failure, or HF. Gencaro was the subject of a Phase 3 heart failure mortality trial involving more than 2,700 patients and was unique in gathering DNA data on over 1,000 of its participants.
Field of Use
The rights granted apply to the healthcare industry relating to heart failure.
IPSCIO Record ID: 26859
License Grant
The Company obtained from a Canadian manufacturer of radiopharmaceuticals, the right to develop and market Viascint in the United States. Upon FDA approval, the Company may sublicense the marketing rights for Viascint.
License Property
Viascint – a sterile radiopharmaceutical formulation of iodine123-iodophenylpentadecanoic acid for injection – subject to FDA approval, as to which no assurance can be given, proposed to be used to determine the presence of hibernating, or reversibly injured heart muscle and thereby predict which patients are most likely to experience improvement in cardiac function following, and thus benefit from, coronary artery bypass graft (CABG) surgery, and to assist physicians in the selection of patients for such surgery.
The Company completed Phase III clinical testing, and the results indicated that the product provides the means to predict, with high accuracy, which patients will have improvement in cardiac functioning following revascularization. The Company filed an NDA in 1996.
Field of Use
The rights granted apply to the heart muscle.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
